1[1]Rosenstock H,Klepzig H,Matter C,et al.Sulfonylures and ischemic preconditioning.A double-blind,placebo-control evaluation of glimepiride and glibenclamide[J].Eur Heart J,1999,20∶439-446.
2[2]Dill RK.Glimepiride:Role of a new sulfonylurea in the treatment of type 2 diabetes mellitus[J].Ann Pharmacother,1998,32∶1044-1052.
3[1]Kramer W, et al. Differential interaction of glimepiride with the β-cell sulfonglurea receptor Ⅱ. Photoaffinity labeling of a 65Kda protein by[3H]glimepiride. Biochim Biophys Acta 1994,1191:278 - 290.
4[2]Miieller G, Harty D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅰ . Binding characteristics. Biophys Acta 1994, 1191:267- 277.
5[3]Cambell RK. Glimepiride: role of a new sulfonylurea in the treament of type 2 diabetes mellitus. Ann Pharmacother, 1998, 32: 1044 -1052.
6[1]Muller G, Hartz D, Punter J, et al. Differential interaction of glimepiride and glibenclamide with the β -cell sulfonylurea receptor Ⅰ. Binding charatteristics[J]. Biochim Biophys Acta,1994; 1191:267-277.
7[2]Kramer W, Muller G, Girbig F, et al. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor Ⅱ. Photoaffinity labeling of a 65 kDa protein by [3H] glimepiride[J]. Biochim Biophys Acta, 994;1191:278-290.
8[3]Sonnenberg GE, Garg DC, Weidler DJ, et al. Short-terrn comparison of once-versus twice-daily administration of glimepiride in patient with non-insulin-dependent diabetes mellitus[J]. Am Pharmacother,1997;31:671-676.
9[4]Muller G, Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at adipocytes[J]. Horm Metab Res, 1996;28:468-487.
10[1]Riveline JP, Danchin N, Ledru F, et al. Sulfonylureas and cardiovascular effects: from experimental data to clinical use.Available data in humans and clinical applications [J].Diabetes Metab,2003,29(3) :207.
